MyFinsight
Home
Blog
About
BURZYNSKI RESEARCH INSTITUTE INC (BZYR)
BURZYNSKI RESEARCH INSTITUTE INC (BZYR)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$1,234
Unit: Dollar
Positive Cash Flow Breakdown
Fda clinical trial expenses paid...
Contribution of capital
Accounts payable
Prepaids
Negative Cash Flow Breakdown
Net loss
Accrued liabilities
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2025-11-30
2025-08-31
2025-05-31
Net loss
-328,862
-333,867
-331,451
Prepaids
-300
-300
700
Accounts payable
21,158
-1,739
8,665
Accrued liabilities
-22,452
1,404
20,088
Net cash used by operating activities
-823,106
-94,907
-49,143
Contribution of capital
86,307
95,017
49,117
Fda clinical trial expenses paid directly by s.r. burzynski m.d., ph.d
244,783
238,995
254,255
Net cash provided by financing activities
824,340
95,017
49,117
Net increase (decrease) in cash
1,234
110
-26
Cash and cash equivalents at beginning of period
931
847
-
Cash and cash equivalents at end of period
2,165
931
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
something is missing
$493,250
Fda clinical trial
expenses paid directly by...
$244,783
Contribution of capital
$86,307
Net cash provided by
financing activities
$824,340
Net increase
(decrease) in cash
$1,234
Canceled cashflow
$823,106
Accounts payable
$21,158
Prepaids
-$300
Net cash used by
operating activities
-$823,106
Canceled cashflow
$21,458
something is missing
-$493,250
Net loss
-$328,862
Accrued liabilities
-$22,452
Buy us a coffee